Management of Acute Severe Hypertension in CKD Patients
Guideline-Based Recommendations
- The European Society of Cardiology recommends IV labetalol for hypertensive crisis management, establishing it as a Class I, Level C recommendation for acute severe hypertension 1
- The target systolic BP for patients with CKD should be 120-129 mmHg based on KDIGO 2021 guidelines, which recommend a target SBP <120 mmHg for adults with CKD and eGFR >30 mL/min/1.73 m² when tolerated 3
Medication Preferences
- Labetalol is the preferred agent over nitroglycerin for acute severe hypertension in CKD patients due to its established safety profile in renal disease and guideline recommendations 1
- Nitroglycerin infusion is reserved for the specific scenario of pre-eclampsia/eclampsia associated with pulmonary edema, not for general hypertensive crisis in CKD 1
Transition to Long-Term Management
- After acute control with labetalol, transition to oral RAS inhibitors (ACE inhibitor or ARB) for long-term management, particularly if the patient has albuminuria 3
- KDIGO guidelines strongly recommend RAS inhibitors as first-line therapy for CKD patients with moderately-to-severely increased albuminuria 3